Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice

Vaccine

Volumn 36, Issue 3, 2018, Pages 371-380

  Hong, Kyung Sook ^a   Ki, Mi Ran ^b   Ullah, H M Arif ^a   Lee, Eun Joo ^a   Kim, Yong Deuk ^a   Chung, Myung Jin ^a   Elfadl, Ahmed K ^a   Park, Jin Kyu ^a   Jeong, Kyu Shik ^a  

^a Kyungpook National University   (South Korea)

^b Korea University   (South Korea)

Author keywords

Anti VacA; Helicobacter pylori; Vaccine

Indexed keywords

HELICOBACTER PYLORI VACCINE; UNCLASSIFIED DRUG; VACUOLATING CYTOTOXIN A EGG YOLK IMMUNOGLOBULIN Y; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN Y; VACA PROTEIN, HELICOBACTER PYLORI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG PURIFICATION; EGG YOLK; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HELICOBACTER INFECTION; HEN; HISTOLOGY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH TISSUE; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; HELICOBACTER PYLORI; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOGLOBULINS; MICE, INBRED C57BL; TREATMENT OUTCOME;

EID: 85040765942     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.11.082     Document Type: Article

References (45)

1. Backert, S., Neddermann, M., Maubach, G., Naumann, M., Pathogenesis of helicobacter pylori infection. Helicobacter 21:Suppl 1 (2016), 19–25.
2. Yong, X., Tang, B., Li, B.S., Xie, R., Hu, C.J., Luo, G., et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal, 2015, 10.1186/s12964-015-0111–0.
3. Atherton, J.C., Cao, P., Peek, R.M. Jr., Tummuru, M.K., Blaser, M.J., Cover, T.L., Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 270 (1995), 17771–17777.
4. Ki, M.R., Lee, H.R., Goo, M.J., Hong, I.H., Do, S.H., Jeong, D.H., et al. Differential regulation of ERK1/2 and p38 MAP kinases in VacA-induced apoptosis of gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 294 (2008), G635–G647.
5. Gebert, B., Fischer, W., Weiss, E., Hoffmann, R., Haas, R., Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301 (2003), 1099–1102.
6. Salama, N.R., Hartung, M.L., Müller, A., Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 11 (2013), 385–399.
7. Van Doorn, L.J., Figueiredo, C., Megraud, F., Pena, S., Midolo, P., Queiroz, D.M., et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 116 (1999), 823–830.
8. Atherton, J.C., Peek, R.M. Jr., Tham, K.T., Cover, T.L., Blaser, M.J., Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112 (1997), 92–99.
9. Tham, K.T., Peek, R.M. Jr., Atherton, J.C., Cover, T.L., Perez-Perez, G.I., Shyr, Y., et al. Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. Hum Pathol 32 (2001), 264–273.
10. Lee, J.Y., Kim, N., Future trends of Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol 63 (2014), 158–170.
11. Svennerholm, A.M., Lundgren, A., Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol 50 (2007), 146–156.
12. Aebischer, T., Schmitt, A., Walduck, A.K., Meyer, T.F., Helicobacter pylori vaccine development: facing the challenge. Int J Med Microbiol 295 (2005), 343–353.
13. Milani, M., Sharifi, Y., Rahmati-Yamchi, M., Somi, M.H., Akbarzadeh, A., Immunology and vaccines and nanovaccines for Helicobacter pylori infection. Expert Rev Vaccines 14 (2015), 833–840.
14. Ayala, G., Escobedo-Hinojosa, W.I., de la Cruz-Herrera, C.F., Romero, I., Exploring alternative treatments for helicobacter pylori infection. World J Gastroenterol 20 (2014), 1450–1469.
15. Muller, S., Schubert, A., Zajac, J., Dyck, T., Oelkrug, C., IgY antibodies in human nutrition for disease prevention. Nutr J, 14, 2015, 109.
16. Wang, B., Yang, J., Cao, S., Wang, H., Pan, X., Zhu, J., et al. Preparation of specific anti-helicobacter pylori yolk antibodies and their antibacterial effects. Int J Clin Exp Pathol 7 (2014), 6430–6437.
17. Malekshahi, Z.V., Gargari, S.L., Rasooli, I., Ebrahimizadeh, W., Treatment of helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 51 (2011), 366–372.
18. Carlander, D., Kollberg, H., Wejaker, P.E., Larsson, A., Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res 21 (2000), 1–6.
19. Tini, M., Jewell, U.R., Camenisch, G., Chilov, D., Gassmann, M., Generation and application of chicken egg-yolk antibodies. Comp Biochem Physiol A Mol Integr Physiol 131 (2002), 569–574.
20. Shin, J.H., Roe, I.H., Kim, H.G., Production of anti-Helicobacter pylori urease-specific immunoglobulin in egg yolk using an antigenic epitope of H. pylori urease. J Med Microbiol 53 (2004), 31–34.
21. Sheu, B.S., Yang, H.B., Wu, J.J., Huang, A.H., Lin, X.Z., Su, I.J., Development of helicobacter pylori infection model in BALB/c mice with domestic cagA-positive and -negative strains in Taiwan. Dig Dis Sci 44 (1999), 868–875.
22. Lee, A., O'Rourke, J., De Ungria, M.C., Robertson, B., Daskalopoulos, G., Dixon, M.F., A standardized mouse model of helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112 (1997), 1386–1397.
23. Ntakarutimana, V., Demedts, P., van Sande, M., Scharpe, S., A simple and economical strategy for downstream processing of specific antibodies to human transferrin from egg yolk. J Immunol Methods 153 (1992), 133–140.
24. Ki, M.R., Hong, I.H., Park, J.K., Hong, K.S., Hwang, O.K., Han, J.Y., et al. Potent neutralization of vacuolating cytotoxin (VacA) of helicobacter pylori by immunoglobulins against the soluble recombinant VacA. Anticancer Res 29 (2009), 2393–2402.
25. Testerman, T.L., McGee, D.J., Mobley, H.L.T., Adherence and colonization. Mobley, H.L.T., Mendz, G.L., Hazell, S.L., (eds.) Helicobacter pylori: physiology and genetics, 2001, ASM Press, Washington (DC) chapter 34.
26. Kubickova, B., Majerova, B., Hadrabova, J., Noskova, L., Stiborova, M., Hodek, P., Effect of chicken antibodies on inflammation in human lung epithelial cell lines. Neuro Endocrinol Lett 35:Suppl 2 (2014), 99–104.
27. Suzuki, H., Nomura, S., Masaoka, T., Goshima, H., Kamata, N., Kodama, Y., et al. Effect of dietary anti-helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 20:Suppl 1 (2004), 185–192.
28. Horie, K., Horie, N., Abdou, A.M., Yang, J.O., Yun, S.S., Chun, H.N., et al. Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci 87 (2004), 4073–4079.
29. Nomura, S., Suzuki, H., Masaoka, T., Kurabayashi, K., Ishii, H., Kitajima, M., et al. Effect of dietary anti-urease immunoglobulin Y on helicobacter pylori infection in Mongolian gerbils. Helicobacter 10 (2005), 43–52.
30. Junaid, M., Linn, A.K., Javadi, M.B., Al-Gubare, S., Ali, N., Katzenmeier, G., Vacuolating cytotoxin A (VacA) - a multi-talented pore-forming toxin from helicobacter pylori. Toxicon 118 (2016), 27–35.
31. Rossi, G., Ruggiero, P., Peppoloni, S., Pancotto, L., Fortuna, D., Lauretti, L., et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 72 (2004), 3252–3259.
32. Malfertheiner, P., Schultze, V., Rosenkranz, B., Kaufmann, S.H., Ulrichs, T., Novicki, D., et al. Safety and immunogenicity of an intramuscular helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135 (2008), 787–795.
33. Borenfreund, E., Puerner, J.A., Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24 (1985), 119–124.
34. Allen, L.A., The role of the neutrophil and phagocytosis in infection caused by helicobacter pylori. Curr Opin Infect Dis 14 (2001), 273–277.
35. Piazuelo, M.B., Camargo, M.C., Mera, R.M., Delgado, A.G., Peek, R.M. Jr., Correa, H., et al. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol 39 (2008), 1360–1369.
36. Papadopoulos, A.A., Tzathas, C., Polymeros, D., Ladas, S.D., Symptomatic eosinophilic gastritis cured with Helicobacter pylori eradication. Gut, 54, 2005, 1822.
37. Soavi, C., Caselli, M., Sioulis, F., Cassol, F., Lanza, G., Zuliani, G., Eosinophilic gastroenteritis cured with Helicobacter pylori eradication: case report and review of literature. Helicobacter 19 (2014), 237–238.
38. Moorchung, N., Srivastava, A.N., Gupta, N.K., Malaviya, A.K., Achyut, B.R., Mittal, B., The role of mast cells and eosinophils in chronic gastritis. Clin Exp Med 6 (2006), 107–114.
39. Rieder, G., Fischer, W., Haas, R., Interaction of helicobacter pylori with host cells: function of secreted and translocated molecules. Curr Opin Microbiol 8 (2005), 67–73.
40. Fahimi, F., Tohidkia, M.R., Fouladi, M., Aghabeygi, R., Samadi, N., Omidi, Y., Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy. Bioimpacts 7 (2017), 59–71.
41. Yamaoka, Y., Mechanisms of disease: helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 7 (2010), 629–641.
42. Palframan, S.L., Kwok, T., Gabriel, K., Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol, 2, 2012, 92.
43. Yang, I., Nell, S., Suerbaum, S., Survival in hostile territory: the microbiota of the stomach. FEMS Microbiol Rev 37 (2013), 736–761.
44. Ki, M.R., Hwang, M., Kim, A.Y., Lee, E.M., Lee, E.J., Lee, M.M., et al. Role of vacuolating cytotoxin VacA and cytotoxin-associated antigen CagA of helicobacter pylori in the progression of gastric cancer. Mol Cell Biochem 396 (2014), 23–32.
45. Foegeding, N., Caston, R., McClain, M., Ohi, M., Cover, T., An overview of helicobacter pylori VacA toxin biology. Toxins, 8, 2016, 173.